Do analysts rate DOCS or RMG?

Dr. Martens presently has a consensus price target of GBX 105, suggesting a potential upside of 46.85%. Given Dr. Martens' stronger consensus rating and higher probable upside, equities research analysts plainly believe Dr. Martens is more favorable than Royal Mail. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Martens 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Royal Mail 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, DOCS or VTY?

Vistry Group has higher revenue and earnings than Dr. Martens. Vistry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Martens £764.90M 0.90 £68.97M £1.70 42.06 Vistry Group £3.61B 0.23 £245.05M £42.00 6.13

Is DOCS or VTY more profitable?

Vistry Group has a net margin of 3.82% compared to Dr. Martens' net margin of 3.11%. Dr. Martens' return on equity of 6.89% beat Vistry Group's return on equity. Company Net Margins Return on Equity Return on Assets Dr. Martens 3.11% 6.89% 8.12% Vistry Group 3.82% 4.20% 3.43%

Which has higher valuation & earnings, GEN or DOCS?

Dr. Martens has higher revenue and earnings than Genuit Group. Genuit Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genuit Group £602.10M 1.05 £23.57M £17.80 14.16 Dr. Martens £764.90M 0.90 £68.97M £1.70 42.06

Is GEN or DOCS more profitable?

Genuit Group has a net margin of 7.51% compared to Dr. Martens' net margin of 3.11%. Genuit Group's return on equity of 6.89% beat Dr. Martens' return on equity. Company Net Margins Return on Equity Return on Assets Genuit Group 7.51% 6.89% 4.59% Dr. Martens 3.11% 6.89% 8.12%

Does the media favor GEN or DOCS?

In the previous week, Genuit Group and Genuit Group both had 4 articles in the media. Dr. Martens' average media sentiment score of 0.71 beat Genuit Group's score of 0.60 indicating that Dr. Martens is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genuit Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Martens 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, DOCS or WIX?

Dr. Martens has higher earnings, but lower revenue than Wickes Group. Wickes Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Martens £764.90M 0.90 £68.97M £1.70 42.06 Wickes Group £1.64B 0.23 £29.25M £16.40 10.48

Is DOCS or WIX more profitable?

Dr. Martens has a net margin of 3.11% compared to Wickes Group's net margin of 2.35%. Wickes Group's return on equity of 29.52% beat Dr. Martens' return on equity. Company Net Margins Return on Equity Return on Assets Dr. Martens 3.11% 6.89% 8.12% Wickes Group 2.35% 29.52% 3.77%

Does the media favor DOCS or WIX?

In the previous week, Dr. Martens had 3 more articles in the media than Wickes Group. MarketBeat recorded 4 mentions for Dr. Martens and 1 mentions for Wickes Group. Dr. Martens' average media sentiment score of 0.71 beat Wickes Group's score of 0.70 indicating that Dr. Martens is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Martens 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Wickes Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dr. Martens (DOCS) Competitors

GBX 71.50 -1.30 (-1.79%)

As of 11:58 AM Eastern

Compare

DOCS vs. RMG, SPT, VTY, GEN, and WIX

Should you buy Dr. Martens stock or one of its competitors? MarketBeat compares Dr. Martens with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dr. Martens include Royal Mail (RMG), Spirent Communications (SPT), Vistry Group (VTY), Genuit Group (GEN), and Wickes Group (WIX). These companies are all part of the "computer software" industry.

How does Dr. Martens compare to Royal Mail?

Dr. Martens (LON:DOCS) and Royal Mail (LON:RMG) are both small-cap computer software companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Dr. Martens presently has a consensus price target of GBX 105, suggesting a potential upside of 46.85%. Given Dr. Martens' stronger consensus rating and higher probable upside, equities research analysts plainly believe Dr. Martens is more favorable than Royal Mail.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Royal Mail	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 3.6%. Royal Mail pays an annual dividend of GBX 0.17 per share. Dr. Martens pays out 150.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royal Mail pays out 27.4% of its earnings in the form of a dividend.

Dr. Martens has a net margin of 3.11% compared to Royal Mail's net margin of 0.00%. Dr. Martens' return on equity of 6.89% beat Royal Mail's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Royal Mail	N/A	N/A	N/A

In the previous week, Dr. Martens had 4 more articles in the media than Royal Mail. MarketBeat recorded 4 mentions for Dr. Martens and 0 mentions for Royal Mail. Dr. Martens' average media sentiment score of 0.71 beat Royal Mail's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the media.

Company	Overall Sentiment
Dr. Martens	Positive
Royal Mail	Neutral

Dr. Martens has higher earnings, but lower revenue than Royal Mail. Royal Mail is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.90	£68.97M	£1.70	42.06
Royal Mail	£12.71B	0.00	N/A	£0.61	N/A

32.2% of Dr. Martens shares are owned by institutional investors. 2.8% of Dr. Martens shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Dr. Martens beats Royal Mail on 12 of the 15 factors compared between the two stocks.

How does Dr. Martens compare to Spirent Communications?

Spirent Communications (LON:SPT) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

57.4% of Spirent Communications shares are held by institutional investors. Comparatively, 32.2% of Dr. Martens shares are held by institutional investors. 22.0% of Spirent Communications shares are held by company insiders. Comparatively, 2.8% of Dr. Martens shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Spirent Communications presently has a consensus target price of GBX 199, indicating a potential upside of 0.10%. Dr. Martens has a consensus target price of GBX 105, indicating a potential upside of 46.85%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Martens is more favorable than Spirent Communications.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spirent Communications	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Dr. Martens had 4 more articles in the media than Spirent Communications. MarketBeat recorded 4 mentions for Dr. Martens and 0 mentions for Spirent Communications. Dr. Martens' average media sentiment score of 0.71 beat Spirent Communications' score of 0.00 indicating that Dr. Martens is being referred to more favorably in the news media.

Company	Overall Sentiment
Spirent Communications	Neutral
Dr. Martens	Positive

Dr. Martens has a net margin of 3.11% compared to Spirent Communications' net margin of 1.53%. Dr. Martens' return on equity of 6.89% beat Spirent Communications' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spirent Communications	1.53%	1.82%	2.77%
Dr. Martens	3.11%	6.89%	8.12%

Spirent Communications has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Dr. Martens has a beta of 0.224, meaning that its stock price is 78% less volatile than the broader market.

Dr. Martens has higher revenue and earnings than Spirent Communications. Dr. Martens is trading at a lower price-to-earnings ratio than Spirent Communications, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spirent Communications	£471M	2.49	£16.67M	£0.01	16,032.26
Dr. Martens	£764.90M	0.90	£68.97M	£1.70	42.06

Summary

Dr. Martens beats Spirent Communications on 11 of the 16 factors compared between the two stocks.

How does Dr. Martens compare to Vistry Group?

Dr. Martens (LON:DOCS) and Vistry Group (LON:VTY) are both small-cap consumer cyclical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Dr. Martens had 4 more articles in the media than Vistry Group. MarketBeat recorded 4 mentions for Dr. Martens and 0 mentions for Vistry Group. Dr. Martens' average media sentiment score of 0.71 beat Vistry Group's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the media.

Company	Overall Sentiment
Dr. Martens	Positive
Vistry Group	Neutral

Vistry Group has a net margin of 3.82% compared to Dr. Martens' net margin of 3.11%. Dr. Martens' return on equity of 6.89% beat Vistry Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Vistry Group	3.82%	4.20%	3.43%

Vistry Group has higher revenue and earnings than Dr. Martens. Vistry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.90	£68.97M	£1.70	42.06
Vistry Group	£3.61B	0.23	£245.05M	£42.00	6.13

Dr. Martens currently has a consensus target price of GBX 105, suggesting a potential upside of 46.85%. Vistry Group has a consensus target price of GBX 531.80, suggesting a potential upside of 106.44%. Given Vistry Group's higher possible upside, analysts plainly believe Vistry Group is more favorable than Dr. Martens.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vistry Group	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10

32.2% of Dr. Martens shares are held by institutional investors. Comparatively, 68.4% of Vistry Group shares are held by institutional investors. 2.8% of Dr. Martens shares are held by insiders. Comparatively, 10.0% of Vistry Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dr. Martens has a beta of 0.224, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Vistry Group has a beta of 1.883, meaning that its stock price is 88% more volatile than the broader market.

Summary

Vistry Group beats Dr. Martens on 9 of the 16 factors compared between the two stocks.

How does Dr. Martens compare to Genuit Group?

Genuit Group (LON:GEN) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Genuit Group and Genuit Group both had 4 articles in the media. Dr. Martens' average media sentiment score of 0.71 beat Genuit Group's score of 0.60 indicating that Dr. Martens is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genuit Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Martens	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genuit Group has a net margin of 7.51% compared to Dr. Martens' net margin of 3.11%. Genuit Group's return on equity of 6.89% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genuit Group	7.51%	6.89%	4.59%
Dr. Martens	3.11%	6.89%	8.12%

Genuit Group has a beta of 1.492, indicating that its share price is 49% more volatile than the broader market. Comparatively, Dr. Martens has a beta of 0.224, indicating that its share price is 78% less volatile than the broader market.

Genuit Group presently has a consensus target price of GBX 430.40, indicating a potential upside of 70.79%. Dr. Martens has a consensus target price of GBX 105, indicating a potential upside of 46.85%. Given Genuit Group's stronger consensus rating and higher possible upside, analysts plainly believe Genuit Group is more favorable than Dr. Martens.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genuit Group	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

74.4% of Genuit Group shares are held by institutional investors. Comparatively, 32.2% of Dr. Martens shares are held by institutional investors. 4.2% of Genuit Group shares are held by company insiders. Comparatively, 2.8% of Dr. Martens shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Genuit Group pays an annual dividend of GBX 12.60 per share and has a dividend yield of 5.0%. Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 3.6%. Genuit Group pays out 70.8% of its earnings in the form of a dividend. Dr. Martens pays out 150.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Genuit Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Dr. Martens has higher revenue and earnings than Genuit Group. Genuit Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genuit Group	£602.10M	1.05	£23.57M	£17.80	14.16
Dr. Martens	£764.90M	0.90	£68.97M	£1.70	42.06

Summary

Genuit Group beats Dr. Martens on 12 of the 17 factors compared between the two stocks.

How does Dr. Martens compare to Wickes Group?

Dr. Martens (LON:DOCS) and Wickes Group (LON:WIX) are both small-cap consumer cyclical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

In the previous week, Dr. Martens had 3 more articles in the media than Wickes Group. MarketBeat recorded 4 mentions for Dr. Martens and 1 mentions for Wickes Group. Dr. Martens' average media sentiment score of 0.71 beat Wickes Group's score of 0.70 indicating that Dr. Martens is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Martens	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Wickes Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Martens has a beta of 0.224, meaning that its share price is 78% less volatile than the broader market. Comparatively, Wickes Group has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Dr. Martens presently has a consensus price target of GBX 105, indicating a potential upside of 46.85%. Wickes Group has a consensus price target of GBX 249.17, indicating a potential upside of 45.03%. Given Dr. Martens' higher possible upside, research analysts clearly believe Dr. Martens is more favorable than Wickes Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Wickes Group	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 3.6%. Wickes Group pays an annual dividend of GBX 10.90 per share and has a dividend yield of 6.3%. Dr. Martens pays out 150.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Wickes Group pays out 66.5% of its earnings in the form of a dividend. Wickes Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Dr. Martens has a net margin of 3.11% compared to Wickes Group's net margin of 2.35%. Wickes Group's return on equity of 29.52% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Wickes Group	2.35%	29.52%	3.77%

Dr. Martens has higher earnings, but lower revenue than Wickes Group. Wickes Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.90	£68.97M	£1.70	42.06
Wickes Group	£1.64B	0.23	£29.25M	£16.40	10.48

32.2% of Dr. Martens shares are held by institutional investors. Comparatively, 57.4% of Wickes Group shares are held by institutional investors. 2.8% of Dr. Martens shares are held by company insiders. Comparatively, 0.4% of Wickes Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Dr. Martens beats Wickes Group on 9 of the 17 factors compared between the two stocks.

Get Dr. Martens News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOCS vs. The Competition

Export

Metric	Dr. Martens	Footwear & Accessories Industry	Cyclical Sector	LON Exchange
Market Cap	£691.54M	£8.75B	£4.04B	£2.78B
Dividend Yield	3.45%	2.00%	3.47%	6.13%
P/E Ratio	42.06	20.70	77.77	364.73
Price / Sales	0.90	41.22	326.27	87,561.71
Price / Cash	14.29	20.28	30.87	27.85
Price / Book	1.89	3.87	3.24	7.74
Net Income	£68.97M	£168.67M	£247.47M	£5.88B
7 Day Performance	-2.32%	-0.07%	0.19%	6.46%
1 Month Performance	15.32%	13.73%	2.47%	9.67%
1 Year Performance	20.07%	15.31%	1.69%	75.31%

Dr. Martens Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOCS Dr. Martens	3.9105 of 5 stars	GBX 71.50 -1.8%	GBX 105 +46.9%	+23.6%	£691.54M	£764.90M	42.06	890	News Coverage Analyst Forecast
RMG Royal Mail	N/A	N/A	N/A	N/A	£1.98B	£12.71B	339.34	100
SPT Spirent Communications	N/A	GBX 198.80 flat	GBX 199 +0.1%	+5.3%	£1.17B	£471M	16,032.26	1,526
VTY Vistry Group	4.149 of 5 stars	GBX 280 +2.7%	GBX 531.80 +89.9%	-57.8%	£889.84M	£3.61B	6.67	4,400	Positive News
GEN Genuit Group	4.7981 of 5 stars	GBX 261.20 +0.8%	GBX 430.40 +64.8%	-36.6%	£657.47M	£602.10M	14.67	2,700	News Coverage Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DOCS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Martens (DOCS) Competitors

DOCS vs. RMG, SPT, VTY, GEN, and WIX

How does Dr. Martens compare to Royal Mail?

Summary

How does Dr. Martens compare to Spirent Communications?

Summary

How does Dr. Martens compare to Vistry Group?

Summary

How does Dr. Martens compare to Genuit Group?

Summary

How does Dr. Martens compare to Wickes Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS vs. The Competition

Dr. Martens Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Martens (DOCS) Competitors

DOCS vs. RMG, SPT, VTY, GEN, and WIX

How does Dr. Martens compare to Royal Mail?

Do analysts rate DOCS or RMG?

Is DOCS or RMG a better dividend stock?

Is DOCS or RMG more profitable?

Does the media refer more to DOCS or RMG?

Which has better earnings and valuation, DOCS or RMG?

Do institutionals and insiders believe in DOCS or RMG?

Summary

How does Dr. Martens compare to Spirent Communications?

Do insiders & institutionals hold more shares of SPT or DOCS?

Do analysts prefer SPT or DOCS?

Does the media favor SPT or DOCS?

Is SPT or DOCS more profitable?

Which has more risk and volatility, SPT or DOCS?

Which has stronger valuation and earnings, SPT or DOCS?

Summary

How does Dr. Martens compare to Vistry Group?

Does the media refer more to DOCS or VTY?

Is DOCS or VTY more profitable?

Which has preferable valuation & earnings, DOCS or VTY?

Do analysts recommend DOCS or VTY?

Do insiders and institutionals have more ownership in DOCS or VTY?

Which has more risk and volatility, DOCS or VTY?

Summary

How does Dr. Martens compare to Genuit Group?

Does the media favor GEN or DOCS?

Is GEN or DOCS more profitable?

Which has more risk & volatility, GEN or DOCS?

Do analysts prefer GEN or DOCS?

Do insiders and institutionals have more ownership in GEN or DOCS?

Is GEN or DOCS a better dividend stock?

Which has higher valuation & earnings, GEN or DOCS?

Summary

How does Dr. Martens compare to Wickes Group?

Does the media favor DOCS or WIX?

Which has more risk & volatility, DOCS or WIX?

Do analysts recommend DOCS or WIX?

Is DOCS or WIX a better dividend stock?

Is DOCS or WIX more profitable?

Which has preferable earnings & valuation, DOCS or WIX?

Do institutionals & insiders have more ownership in DOCS or WIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS vs. The Competition

Dr. Martens Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools